ECI BIOTECH APPOINTS ADRIAN LOWE DIRECTOR OF MICROBIAL GENETICS

ECI Biotech, a protein design and expression company based in Worcester, MA, today announced that Adrian Lowe, Ph.D., a Newton resident, has been named Director of Microbial Genetics.

ECI BIOTECH APPOINTS ADRIAN LOWE
DIRECTOR OF MICROBIAL GENETICS

DATELINE: WORCESTER, MA; OCTOBER 19, 2001 –
ECI Biotech, a protein design and expression company based in Worcester, MA, today announced that Adrian Lowe, Ph.D., a Newton resident, has been named Director of Microbial Genetics.

"Adrian is an exceptional scientist and an important addition to our staff," said Mitch Sanders, President of ECI Biotech. "He has broad experience in the areas of pathogenic bacteria, pharmacology, assay development, and production of therapeutic proteins. Adrian's expertise in these areas will be important to our continued development of new protein technologies and therapeutic applications."

"At ECI Biotech, Adrian will be responsible for our Wound Infection Program that is focused on the development of wound dressings that will change color in the presence of harmful bacteria, such as Staphylococcus."

Prior to joining ECI Biotech, Dr. Lowe was Senior Scientist II for the biologics development team of AVANT Immunotherapeutics Inc. He has held teaching appointments at Harvard Medical School's Channing Laboratory and at the University of Bath, in England. He holds two U.S. patents and has published articles on protein cloning and technology in several professional journals.

Dr. Lowe holds a Ph.D. in molecular microbiology from the University of Bath, in England. He completed postdoctoral training at Harvard University Medical School.

ECI Biotech, headquartered in Worcester, Massachusetts, is a protein design company focused on the dynamics of protein structure. Proteins are dynamic and complex molecules that perform almost every essential function of living things. ECI Biotech has developed two distinct technologies based on monitoring and preserving protein structure: "protector proteins" enhance protein stability and functioning in unfavorable

conditions, while "detector proteins" sense changes in protein structure that indicate a chemical shift in the environment. ECI Biotech intends to license its protein technologies for use in large industries with unmet needs, including food safety, medical diagnostics, industrial chemistry and consumer goods. ECI Biotech's product pipeline includes a diagnostic kit for detecting the pathogenic bacteria Listeria monocytogenes, a leading cause of meat and poultry recalls, as well as two advanced wound care systems designed to provide early warning of emergent infections and to promote healing.

For more information about ECI Biotech and its protein technologies, please visit www.ecibiotech.com, or contact Mitchell Sanders at (508) 752-2209.